Differences in tumor thickness between hematoxylin and eosin and Melan-A immunohistochemically stained primary cutaneous melanomas

American Journal of Dermatopathology

Volumn 35, Issue 1, 2013, Pages 56-63

  Drabeni, Marina ^a   Lopez Vilaró, Laura ^b   Barranco, Carlos ^b   Trevisan, Giusto ^a   Gallardo, Fernando ^b   Pujol, Ramon M ^b  

^a UNIVERSITY OF TRIESTE   (Italy)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Breslow thickness; Melan A; Melanoma

Indexed keywords

EOSIN; HEMATOXYLIN; MELAN A;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER CLASSIFICATION; CANCER INVASION; CUTANEOUS MELANOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY INFILTRATE; MAJOR CLINICAL STUDY; MALE; PRIMARY TUMOR; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; COLORING AGENTS; EOSINE YELLOWISH-(YS); FEMALE; HEMATOXYLIN; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MART-1 ANTIGEN; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; OBSERVER VARIATION; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; STAINING AND LABELING; TUMOR MARKERS, BIOLOGICAL;

EID: 84873407507     PISSN: 01931091     EISSN: 15330311     Source Type: Journal    
DOI: 10.1097/DAD.0b013e31825ba933     Document Type: Article

References (42)

1. Breslow A. Thickness, cross-sectional area and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg. 1970;172:902-908.
2. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199-6209.
3. Colloby PS, West KP, Fletcher A. Observer variation in the measurement of Breslow depth and Clark's level in cutaneous malignant melanoma. J Pathol. 1990;163:245-250.
4. Scolyer RA, Shaw HM, Thompson JF, et al. Interobserver reproducibility of histopathologic prognostic variables in primary cutaneous melanomas. Am J Surg Pathol. 2003;27:1571-1576.
5. Suffin SC, Waisman J, Clark WH Jr, et al. Comparison of the classification by microscopic level (stage) of malignant melanoma by three independent groups of pathologists. Cancer. 1977;40:3112-3114.
6. Hurt MA, Santa Cruz DJ. Malignant melanoma microstaging. History, premises, methods, problems, and recommendations - A call for standardization. Pathol Annu. 1994;29:51-74.
7. Prade M, Sancho-Garnier H, Cesarini JP, et al. Difficulties encountered in the application of Clark classification and the Breslow thickness measurement in cutaneous malignant melanoma. Int J Cancer. 1980; 26:159-163.
8. Prieto VG, Shea CR. Use of immunohistochemistry in melanocytic lesions. J Cutan Pathol. 2008;35(suppl 2):1-10.
9. Plaza JA, Suster D, Perez-Montiel D. Expression of immunohistochemical markers in primary and metastatic malignant melanoma: A comparative study in 70 patients using a tissue microarray technique. Appl Immunohistochem Mol Morphol. 2007;5:421-425.
10. Ramos-Herberth FI, Karamchandani J, Kim J, et al. SOX10 immunostaining distinguishes desmoplastic melanoma from excision scar. J Cutan Pathol. 2010;37:944-952.
11. Breslow A. Problems in the measurement of tumor thickness and level of invasion in cutaneous melanoma, Hum Pathol. 1977;8:1-2.
12. Breslow A. Prognosis in cutaneous melanoma: Tumor thickness as a guide to treatment. Pathol Annu. 1980;15(pt 1):1-22.
13. de Vries TJ, Smeets M, de Graaf R, et al. Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional lymph node, and visceral metastases: Implications for diagnosis and immunotherapy. A study conducted by the EORTC melanoma Cooperative Group. J Pathol. 2001;193:13-20.
14. Ohsie SJ, Sarantopoulos GP, Cochran AJ, et al. Immunohistochemical characteristics of melanoma. J Cutan Pathol. 2008;35:433-444.
15. Hillesheim PB, Slone S, Kelley D, et al. An immunohistochemical comparison between MiTF and MART-1 with Azure blue counterstaining in the setting of solar lentigo and melanoma in situ. J Cutan Pathol. 2011; 38:565-569.
16. Coulie PG, Brichard V, Van Pel A, et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 1994;180:35-42.
17. Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A. 1994;91:3515-3519.
18. Orchard GE. Melan A (MART-1): A new monoclonal antibody for malignant melanoma diagnosis. Br J Biomed Sci. 1998;55:8-9.
19. Kageshita T, Kawakami Y, Hirai S, et al. Differential expression of MART-1 in primary and metastatic melanoma lesions. J Immunother. 1997;20:460-465.
20. Kaufmann O, Koch S, Burghardt J, et al. Tyrosinase, melan-A and KBA62
21. as markers for the immunohistochemical identification of metastatic amelanotic melanomas on paraffin sections. Mod Pathol. 1998;11:740-746.
22. Clarkson KS, Sturdgess IC, Molyneux AJ. The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: A comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103(anti-melan-A). J Clin Pathol. 2001;54:196-200.
23. Busam KJ, Jungbluth AA. Melan-A, a new melanocytic differentiation marker. Adv Anat Pathol. 1999;6:12-18.
24. Busam KJ, Chen YT, Old LJ, et al. Expression of MART-1 in benign melanocytic nevi and primary cutaneous malignant melanoma. Am J Surg Pathol. 1998;22:976-982.
25. Reinke S, Königer P, Herberth G, et al. Differential expression of MART-1, tyrosinase and SM5-1 in primary and metastatic melanoma. Am J Dermatopathol. 2005;27:401-406.
26. Jungbluth AA, Busam KJ, Gerald WL, et al. A103: An anti-melan-A monoclonal antibody for the detection of malignant melanoma in paraffin- embedded tissues. Am J Surg Pathol. 1998;22:595-602.
27. Berset M, Cerottini JP, Guggisberg D, et al. Expression of Melan-A/ Mart-1 antigen as a prognostic factor in primary cutaneous melanoma. Int J Cancer. 2001;95:73-77.
28. Hofbauer GF, Kamarashev J, Geertsen R, et al. Melan A MART-1
29. immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: Frequency and distribution. Melanoma Res. 1998;8:337-343.
30. Megahed M, Schön M, Selimovic D, et al. Reliability of diagnosis of melanoma in situ. Lancet. 2002;359:1921-1922.
31. Thum C, Hollowood K, Birch J, et al. Aberrant Melan-A expression in atypical fibroxanthoma and undifferentiated pleomorphic sarcoma of the skin. J Cutan Pathol. 2011;38:954-960.
32. El Shabrawi-Caelen L, Kerl H, Cerroni L. Melan-A: Not a helpful marker in distinction between melanoma in situ on sun-damaged skin and pigmented actinic keratosis. Am J Dermatopathol. 2004;26:364-366.
33. Maize JC Jr, Resneck JS Jr, Shapiro PE, et al. Ducking stray "magic bullets": A Melan-A alert. Am J Dermatopathol. 2003;25:162-165.
34. Andres C, Flaig MJ. Pitfalls of Melan-A staining. J Cutan Pathol. 2010; 37:917-918.
35. Beltraminelli H, El Shabrawi-Caelen L, Kerl H, et al. Melan-A-Positive "pseudomelanocytic nests": A pitfall in the histopathologic and immunohistochemical diagnosis of pigmented lesions on sun-damaged skin. Am J Dermatopathol. 2009;31:305-308.
36. Demartini CS, Dalton MS, Ferringer T, et al. Melan-A/MART-1 positive "pseudonests" in lichenoid inflammatory lesions: An uncommon phenomenon. Am J Dermatopathol. 2005;27:370-371.
37. França AF, de Souza EM. Histopathology and immunohistochemistry of depigmented lesions in lupus erythematosus. J Cutan Pathol. 2010;37: 559-564.
38. Gavino AC, Woods MT, Andea AA. MART-1 is a reliable melanocytic marker in lichen planus-like keratosis: A study on 70 cases. Am J Dermatopathol. 2011;33:675-680.
39. Silva CY, Goldberg LJ, Mahalingam M, et al. Nests with numerous SOX10 and MiTF-positive cells in lichenoid inflammation: Pseudomelanocytic nests or authentic melanocytic proliferation? J Cutan Pathol. 2011;38:797-800.
40. Kim J, Taube J, McCalmont TH, et al. Quantitative comparison of MiTF, Melan-A, HMB-45 and Mel-5 in solar lentigines and melanoma in situ. J Cutan Pathol. 2011;38:775-779.
41. Wiltz KL, Qureshi H, Patterson JW, et al. Immunostaining for MART-1 in the interpretation of problematic intra-epidermal pigmented lesions. J Cutan Pathol. 2007;34:601-605.
42. Helm K, Findeis-Hosey J. Immunohistochemistry of pigmented actinic keratoses, actinic keratoses, melanomas in situ and solar lentigines with Melan-A. J Cutan Pathol. 2008;35:931-934.